Drug Type CRISPR/Cas |
Synonyms ADGN-PCSK9 |
Target |
Mechanism PCSK9 modulators(Proprotein convertase subtilisin kexin type 9 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypercholesterolemia | Preclinical | US | 07 May 2024 | |
Hypercholesterolemia | Preclinical | FR | 07 May 2024 |